Navigation Links
Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
Date:3/25/2009

, chief medical officer of Poniard. "The data from this trial is event-driven and we expect that the overall survival data from the SPEAR trial will show a significant survival advantage compared to patients who receive best supportive care alone. We believe this is the first important step to provide a new treatment option for the many SCLC patients who do not achieve clinical benefit from current first-line therapies. This would be a significant accomplishment for this aggressive tumor type that has very few FDA-approved drugs."

SPEAR Trial Design

The international, multi-center, randomized, controlled, pivotal Phase 3 SPEAR trial compares picoplatin plus best supportive care, to best supportive care alone, to evaluate the efficacy and safety of picoplatin after relapse. Best supportive care includes care and treatment to optimize the comfort of patients and their ability to function, as well as to minimize the side effects of palliative cancer treatments. The primary efficacy endpoint is overall survival. Overall response rates, progression-free survival and disease control are also being evaluated.

The SPEAR trial is being conducted under the review of an independent Data Monitoring Committee, which assesses use of best supportive care to ensure balance in both arms of the trial, as well as the use of picoplatin and its safety in the treatment arm. The trial is also being conducted under a Special Protocol Assessment (SPA) developed with the FDA.

Poniard has received Orphan Drug and Fast Track designations for picoplatin for the second-line treatment of refractory or resistant SCLC from the FDA, and Orphan Drug designation from the European Commission for medicinal product status for SCLC.

About Picoplatin

Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date indicate that it has an improved saf
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Kiromic, LLC, a ... of Kent Hance , the former chancellor of Texas ... retired as chancellor in July 2014, after raising $1.2 billion ... that Kent Hance , the most successful chancellor in ... team not only as an investor, but also as our ...
(Date:9/19/2014)... , September 19, 2014 ... by Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, ... (Hospitals), Advanced technologies - Global Forecast to 2019" ... poised to reach $19,786.3 Million by 2019 from ... 6.8% from 2014 to 2019. Browse ...
(Date:9/19/2014)... , Sept. 19, 2014  4WEB Medical announces ... 3D-printed foot and ankle osteotomy implants on the ... Ankle Society annual meeting in Chicago ... all of a surgeon,s osteotomy needs with 74 size options ... systems had smaller offerings of only 15 to 18 implant ...
Breaking Medicine Technology:Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 44WEB Medical Unveils 3D-Printed Osteotomy Truss System 2
... ... pay the United States $1.375 million to resolve False Claims Act ... of a sham durable medical equipment (DME) provider, the Justice Department ... MediNet Corp. provided the kickbacks and assistance and, in return, Harborside ...
... Industry Distributors Association (HIDA) announces the launch of a ... value of medical products distribution. , "Nearly one hundred ... delivered by a distributor, yet few people understand the ... it more efficient," said Matthew J. Rowan, HIDA,s president ...
Cached Medicine Technology:Harborside Healthcare to Pay U.S. $1.375 Million to Resolve Allegations of Kickbacks and Sham Durable Medical Services 2
(Date:9/21/2014)... While public health authorities focus on the physical activity ... University of Montreal reveals that for children, playing has ... an activity that is fun, done alone or with ... or pleasure, but also to combat boredom, sadness, fear, ... of play, authorities put aside several aspects of play ...
(Date:9/21/2014)... roasted peanuts are more likely to trigger an allergy ... study involving mice. , The researchers say that specific ... dry roasting process are recognised by the body,s immune ... immune response the next time it sees any peanuts. ... number of people with peanut allergies in the Western ...
(Date:9/21/2014)... The Laboratory Testing Services industry is ... tests on items ranging from consumer and food products ... on operators to ensure the safety and quality of ... of government safety regulations and consumer lawsuits have led ... Although revenue briefly dipped in 2009 as the US ...
(Date:9/21/2014)... "I wanted to be able to obtain a ... energy drinks," said an inventor from Fresh Meadows, N.Y. ... plain, old coffee. That is why I came up ... CHEWING GUM to provide a healthy energy boost that ... nutritious vitamins, minerals and antioxidants. It also features a ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 The ... BHWG) will host a statewide symposium ( tinyurl.com/ILBHC14 ... Veterans, and their Families. Sponsored by the VNA ... Lottery Cash Grant, and Health & Disability Advocates, ... at the Hilton Hotel in Springfield, IL. ...
Breaking Medicine News(10 mins):Health News:Narrow focus on physical activity could be ruining kids' playtime 2Health News:Dry roasting could help trigger peanut allergy 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 3
... LUNA and the Breast Cancer Fund Launch National Campaign to Inspire ... Educate that Prevention is ... be diagnosed with breast cancer in their lifetime. Although 50 percent,of ... sufferers have a genetic history of the disease. LUNA, the ...
... Mich., Oct. 29 American,Physicians Capital, Inc. (Nasdaq: ... has authorized the repurchase of an additional $20,million of ... under Rule 10b5-1,of the Securities Exchange Act of 1934. ... dollars allocated to the 2007 10b5-1 plan,adopted by the ...
... to Ongoing Oncology Program for MDX-1106, PRINCETON, ... Medarex, Inc. (Nasdaq: MEDX ) announced today ... filed with the U.S. Food &,Drug Administration (FDA) ... Ltd.), a fully human anti-PD-1 antibody being,investigated for ...
... the 2007 third quarter includes $1.8 million of first ... commercial products, DUBLIN, Calif., Oct. 29 SuperGen ... the discovery, rapid,development and commercialization of therapies for solid ... third,quarter and nine months ended September 30, 2007. ...
... with first-ever attack, babies, and people with AIDS, guideline ... CT brain scans should be used to screen certain ... the right kind of treatment, according to a new ... The guideline authors analyzed all available scientific evidence on ...
... for evaluating the eyes ability to distinguish object details ... could provide a more accurate way to assess the ... devices and training, according to a Canadian study. The ... illumination targets for testing spatial vision, which the authors ...
Cached Medicine News:Health News:LUNA Pure Prevention Survey Confirms Breast Cancer Misconceptions 2Health News:LUNA Pure Prevention Survey Confirms Breast Cancer Misconceptions 3Health News:American Physicians Capital, Inc. Authorizes Additional $20 Million Share Buyback 2Health News:Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody 2Health News:Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody 3Health News:Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody 4Health News:SuperGen Reports 2007 Third Quarter Financial Results 2Health News:SuperGen Reports 2007 Third Quarter Financial Results 3Health News:SuperGen Reports 2007 Third Quarter Financial Results 4Health News:SuperGen Reports 2007 Third Quarter Financial Results 5Health News:SuperGen Reports 2007 Third Quarter Financial Results 6Health News:SuperGen Reports 2007 Third Quarter Financial Results 7Health News:SuperGen Reports 2007 Third Quarter Financial Results 8Health News:SuperGen Reports 2007 Third Quarter Financial Results 9Health News:SuperGen Reports 2007 Third Quarter Financial Results 10Health News:Certain Seizure Patients Need Emergency CT Scan 2Health News:Test for visual acuity could aid detection, rehabilitation of AMD 2
... Design Holds The Lens Securely During ... Blades Keep The Optic From Being ... Over Release Of The Optic.,Wide Jaw ... During Insertion.,Reusable, Autoclaveable, Made In The ...
... Unique In-Line Footplates Are Turned 90 ... The Diamond Blade While Incising Tissue. ,Special ... Blade Depth Penetration.,Pre-Set Blade Extension Settings ... Retraction And Full Extension.,1mm Wide Snub ...
2.5V Halogen source, fiber-optic delivery, 2.5X magnification....
Pocket-sized instrument with 2.5X magnification....
Medicine Products: